Progressive improvements in efficacy and disability with fremanezumab in patients with medication overuse and inadequate response to multiple migraine preventive medication classes

Abstract

Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has demonstrated efficacy for migraine prevention in patients with episodic or chronic migraine (EM or CM) with documented inadequate response to 2–4 classes of prior preventive migraine medications in the phase 3b FOCUS study. This subgroup analysis evaluated the efficacy of fremanezumab in patients with baseline medication overuse (simple analgesics ≥15 days/month of triptans, ergots, barbiturate- or opioid-containing analgesics ≥10 days/month).